表紙
市場調査レポート

EpiCast Report:世界の慢性骨髄性白血病(CML)の疫学的予測

EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 268831
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
EpiCast Report:世界の慢性骨髄性白血病(CML)の疫学的予測 EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022
出版日: 2013年04月12日 ページ情報: 英文 43 Pages
概要

世界の主要国における慢性骨髄性白血病の発症件数は、2012年の10,645件から2022年には12,252件と、10年間で15.1%増加すると予想されています。また、有病者数も2012年の45,000件から2012年には51,000件にまで増加すると見られています。他方、チロシンキナーゼ阻害薬療法などの開発・普及により、死亡率は今後低下するものと思われます。

当レポートでは、世界の主要7ヶ国(フランス・ドイツ・イタリア・スペイン・英国・米国・日本)における慢性骨髄性白血病(CML)の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の罹患・普及状況、今後10年間の発症件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概況
  • 関連調査

第3章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
    • 電離放射線への被爆は、必ずしも慢性骨髄性白血病(CML)の発生につながらない
    • 肥満や成人の体重増加は、慢性骨髄性白血病リスクに大きく影響する
  • 世界的な傾向
    • 発症率
    • 有病率・生存率
    • 死亡率
  • 予測手法
    • 利用した情報源
    • 予測の仮定・手法:発症率の場合
    • 予測の仮定・手法:有病率の場合
    • 利用しなかった情報源
  • 慢性骨髄性白血病の疫学的予測:今後10年間分
    • 発症率(全体)
    • 発症率(年齢層別)
    • 発症率(男女別)
    • 年齢調整された発症率
    • 発症率(Ph+の有無別)
    • 発症率(診断の段階別)
    • 有病率
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER014

Summary

Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells originating in the bone marrow that invade the blood and potentially other organs, depending on the phase of the cancer (ACS, 2012; NLM, 2012). Based on clinical characteristics and laboratory findings, CML is divided into three phases: chronic, accelerated, and blast crisis; most people with CML are diagnosed at the chronic phase (NLM, 2012). The diagnosis of CML is based on the presence of the Philadelphia (Ph) chromosome, which is the product of a distinctive cytogenetic abnormality where the BCR gene on chromosome 22 becomes fused to the ABL gene on chromosome 9, generating the BCR-ABL fusion oncogene, which produces the BCR-ABL protein and triggers CML. The Ph chromosome is present in 95% of CML patients (Jabbour and Kantarjian, 2012; Sawyers, 1999).

GlobalData forecasts that the number of incident cases of CML in the 7MM will increase by 15.1% over the next decade, from 10,645 cases in 2012 to 12,252 cases in 2022. The number of five-year prevalent cases of CML in the 7MM will increase from approximately 45,000 cases to more than 51,000 cases throughout the forecast. In addition, the number of 10-year prevalent cases of CML in the 7MM will increase by 15.2% from 2012 to 2022. Country-specific registries are currently updating their CML prevalence data to reflect improved survival due to tyrosine kinase inhibitor therapy. As a result, the forecast number of prevalent cases of CML may increase toward the end of the forecast period as the disease survival continues to improve.

Scope

  • The chronic myeloid leukemia (CML) EpiCast Report provides an overview of the risk factors and global trends associated with CML in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan).
  • It also includes a 10-year epidemiological forecast of the incident and five- and 10-year prevalent cases of CML segmented by sex and age (by five-year increments for all age groups) in the seven major markets.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global CML market.
  • Quantify patient populations in the global CML market to improve product development, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying sex and age groups that present the best opportunities for CML therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Exposure to ionizing radiation may not lead to the development of CML
    • 3.2.2. Obesity and weight gain in adulthood play important roles in CML risk
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Prevalence and Survival
    • 3.3.3. Mortality
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods, Incident Cases
    • 3.4.3. Forecast Assumptions and Methods, Prevalent Cases
    • 3.4.4. Sources Not Used
  • 3.5. Epidemiological Forecast of Chronic Myeloid Leukemia (2012-2022)
    • 3.5.1. Incident Cases of Chronic Myeloid Leukemia
    • 3.5.2. Incident Cases of Chronic Myeloid Leukemia by Age Group
    • 3.5.3. Incident Cases of Chronic Myeloid Leukemia by Sex
    • 3.5.4. Age-Standardized Incidence Rates of Chronic Myeloid Leukemia
    • 3.5.5. Incident Cases of Chronic Myeloid Leukemia with Ph+
    • 3.5.6. Incident Cases of Chronic Myeloid Leukemia by Phase at Diagnosis
    • 3.5.7. Prevalent Cases of Chronic Myeloid Leukemia
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Clinical Trials Analysis
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Contact Us
  • 4.6. Disclaimer

List of Tables

  • Table 1: Reported Incidence of Chronic Myeloid Leukemia for the US, 5EU, and Japan
  • Table 2: US, Annual Percentage Change (APC) in CML Mortality Rates, by Sex, Ages 0-85+ Years, %, 1993-2008
  • Table 3: 7MM, Sources of CML Incidence and Prevalence Data
  • Table 4: 7MM, Incident Cases of Chronic Myeloid Leukemia, Ages 0-85+ Years, Men and Women, N, 2012-2022
  • Table 5: 7MM, Incident Cases of CML, by Age Group, Men and Women, N (Column %)*, 2012
  • Table 6: 7MM, Incident Cases of CML, by Sex, 0-85+ Years, N (Row %), 2012
  • Table 7: 7MM, Incident Cases of CML, by Ph+, Men and Women, 0-85+ Years, N, 2012
  • Table 8: 7MM, Incident Cases of CML, by Phase at Diagnosis, Men and Women, 0-85+ Years, N, 2012
  • Table 9: 7MM, Five- and 10-Year Prevalent Cases of Chronic Myeloid Leukemia, Ages ≥0 Years, Men and Women, N, 2012-2022

List of Figures

  • Figure 1: 7MM, Incident Cases of Chronic Myeloid Leukemia, Ages 0-85+ Years, Men and Women, N, 2012-2022
  • Figure 2: 7MM, Incident Cases of Chronic Myeloid Leukemia, by Age Group, Men and Women, N, 2012
  • Figure 3: 7MM, Incident Cases of Chronic Myeloid Leukemia, Ages 0-85+, By Sex , N, 2012
  • Figure 4: 7MM, Age-Standardized Incidence of Chronic Myeloid Leukemia, Ages ≥0 Years, Men and Women , N , 2012
  • Figure 5: 7MM, Incident Cases of Chronic Myeloid Leukemia, by Phase at Diagnosis, Ages 85+ Years, Men and Women, N, 2012
  • Figure 6: 7MM, Five-Year Prevalent Cases of Chronic Myeloid Leukemia, Ages ≥0 Years, Men and Women, N, 2012-2022
  • Figure 7: 7MM, 10-Year Prevalent Cases of Chronic Myeloid Leukemia, Ages ≥0 Years, Men and Women, N, 2012-2022
Back to Top